FDA urges QbD approach for transdermal patches
This article was originally published in The Gold Sheet
Executive Summary
FDA asked manufacturers in an Aug. 3 draft guidance document to use quality-by-design approaches to minimize the amount of residual drug left in transdermal patches. The guidance notes that currently marketed transdermal patches may retain 10 to 95 percent of the initial total amount of the drug after the intended use, raising a potential safety issue for patients and their family members
You may also be interested in...
Drug Patch Manufacturers Can Skip Quality By Design Approach, FDA Says
Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.